Werewolf Therapeutics to Merge with Ambros Therapeutics in $500M All-Stock Deal with $150M PIPE
HOWL has more than doubled off its 52-week low of $0.27 on elevated volume (38× avg).
Summary
Werewolf Therapeutics announced a definitive merger with Ambros Therapeutics, a reverse merger valuing Ambros at $500M and Werewolf at $47.5M, with a concurrent $150M PIPE. The combined company will focus on neridronate for CRPS-1, with Phase 3 data expected in 2028.
Key Events · M&A and Partnerships · HOWL
-
Reverse Merger with Ambros Therapeutics
Werewolf will acquire Ambros in an all-stock transaction, with Ambros stockholders receiving 71.7% of the combined company and Werewolf stockholders retaining only 6.8%. The deal values Ambros at $500M and Werewolf at $47.5M.
-
$150M Concurrent PIPE Financing
A $150M private placement from healthcare investors including RA Capital and Janus Henderson will close concurrently with the merger. Proceeds fund operations through Phase 3 topline data expected in 2028 and NDA submission, with cash runway into 1H 2029.
-
Contingent Value Rights for Legacy Assets
Werewolf stockholders will receive one CVR per share, entitling them to payments from any future monetization of legacy assets WTX-124 and WTX-330. No payments are guaranteed.
-
Neridronate Phase 3 Program
The combined company will focus on neridronate for CRPS-1, which has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. The pivotal CRPS-RISE trial is ongoing with topline data expected in 2028.
Analysis · HOWL · Life Sciences
Werewolf Therapeutics entered into a definitive merger agreement with Ambros Therapeutics, a clinical-stage biotech developing neridronate for CRPS-1. The deal values Ambros at $500M and Werewolf at $47.5M, with pre-merger Werewolf stockholders owning only 6.8% of the combined company. A concurrent $150M PIPE from leading healthcare investors will fund operations through Phase 3 topline data expected in 2028. This is a transformative reverse merger that effectively hands control to Ambros stockholders while providing Werewolf shareholders with a CVR for legacy assets. The transaction addresses Werewolf's going concern warning and Nasdaq delisting risk by recapitalizing the company with a late-stage asset and significant cash runway.
At the time of this filing, HOWL was trading at $1.04 on NASDAQ in the Life Sciences sector. The 52-week trading range was $0.27 to $2.38. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.